ArticlePharmacoEconomics - open2021

Cost-Utility Analysis of Dolutegravir- Versus Efavirenz-Based Regimens as a First-Line Treatment in Adult HIV/AIDS Patients in Ethiopia.

Yared Belete Belay et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.